Last Updated: November 16, 2026

Details for Patent: 8,283,380

« Back to Dashboard


Which drugs does patent 8,283,380 protect, and when does it expire?

Patent 8,283,380 protects XADAGO and is included in one NDA.

This patent has forty-four patent family members in twenty-six countries.

Summary for Patent: 8,283,380
Title:Methods for treatment of parkinson's disease
Abstract:New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists.
Inventor(s):Ruggero Fariello, Carlo Cattaneo, Patricia Salvati, Luca Benatti
Assignee: Newron Pharmaceuticals SpA
Application Number:US10/559,982
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,283,380
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

United States Drug Patent 8,283,380: Safinamide Parkinson’s Disease Claims, Scope, Expiration and Patent Landscape

U.S. Patent No. 8,283,380 protects a treatment method using oral safinamide, including safinamide methanesulfonate, together with a stable levodopa regimen for idiopathic Parkinson’s disease. The core protection is a combination-use claim, not a broad claim to safinamide, levodopa, or Parkinson’s treatment generally. The principal commercial relevance is Xadago, the safinamide product approved by the FDA in 2017 as an adjunct to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.[1]

The patent’s strongest enforcement position is against an ANDA applicant that proposes safinamide for the FDA-approved adjunctive use, at an oral once-daily dose within the claimed range, during continued levodopa therapy. The patent does not directly cover safinamide monotherapy, non-oral administration, or treatment of Parkinsonian conditions other than idiopathic Parkinson’s disease.

What patent protects safinamide treatment with levodopa?

U.S. Patent 8,283,380 is directed to methods of treating idiopathic Parkinson’s disease by administering safinamide concurrently with levodopa. The patent was granted on October 9, 2012, and is associated with Newron Pharmaceuticals S.p.A., the developer of safinamide.[2]

Field Patent 8,283,380
U.S. patent 8,283,380
Subject matter Safinamide adjunctive treatment with levodopa
Therapeutic area Idiopathic Parkinson’s disease
Route Oral safinamide administration
Claimed dose About 0.5 mg/kg/day to about 5 mg/kg/day
Narrower dose limitation No more than about 200 mg/day
Administration frequency Once daily in dependent claim 6
Safinamide form Safinamide or pharmaceutically acceptable salt; methanesulfonate in claim 7
Background levodopa Stable dose
Additional agents Carbidopa, benserazide, tolcapone, or entacapone
Grant date October 9, 2012
Patent owner or originating applicant Newron Pharmaceuticals S.p.A.
Expected nominal expiration Approximately March 2027, subject to the USPTO term calculation and any applicable adjustments

The patent is a method-of-treatment patent. It does not claim safinamide as a chemical compound, safinamide methanesulfonate as a composition, or every use of safinamide in neurology.

What are the independent claims of U.S. Patent 8,283,380?

Claims 1 and 2 are the independent claims.

Claim 1 is an improvement claim. It assumes that the patient is already receiving a stable levodopa dose and requires concurrent administration of safinamide at approximately 0.5 to 5 mg/kg/day.

Claim 2 is structured as a complete treatment method. It requires:

  1. Administration of a therapeutically effective stable dose of levodopa; and
  2. Concurrent oral administration of safinamide at approximately 0.5 to 5 mg/kg/day.

The distinction matters in litigation. Claim 1 presents safinamide as an improvement to an existing levodopa regimen. Claim 2 expressly recites both levodopa and safinamide as components of the treatment method.

Claim-by-claim scope analysis

Claim Additional limitation Practical scope
1 Stable levodopa dose, idiopathic Parkinson’s disease, concurrent oral safinamide, 0.5-5 mg/kg/day Core adjunctive-use claim
2 Stable therapeutic levodopa dose plus concurrent oral safinamide, 0.5-5 mg/kg/day Parallel core treatment claim
3 No more than about 5 mg/kg/day Narrows the dose ceiling, although the limitation largely overlaps the upper boundary of claims 1 and 2
4 No more than about 200 mg/day Fixed daily-dose limitation
5 Administration for at least 12 weeks Duration limitation
6 Once-daily administration Frequency limitation aligned with commercial dosing
7 Safinamide methanesulfonate Covers the salt used in Xadago
8 Levodopa with carbidopa or benserazide Covers standard peripheral decarboxylase-inhibitor combinations
9 Additional catechol-O-methyltransferase inhibitor Adds COMT inhibition to the treatment regimen
10 Tolcapone or entacapone Narrows claim 9 to specified COMT inhibitors

The claims are cumulative. For example, an accused regimen that uses safinamide methanesulfonate once daily for 12 weeks with levodopa/carbidopa may implicate claims 1, 2, and 5 through 8, depending on dose and the facts established in the case.

What conditions must be met to infringe the patent?

A potentially infringing regimen generally must satisfy each required element of an asserted claim. For the broadest claims, the relevant elements are:

  • The patient has idiopathic Parkinson’s disease.
  • The patient receives levodopa at a stable dose.
  • Safinamide is administered concurrently.
  • Safinamide is administered orally.
  • The dose is approximately 0.5 to 5 mg/kg/day.
  • The administration is therapeutic in the context of treating Parkinson’s disease.

The word “concurrently” does not necessarily require simultaneous ingestion. In ordinary pharmaceutical-use analysis, the issue is whether safinamide and levodopa are used as part of the same treatment regimen. The precise interpretation would depend on the patent specification, prosecution history, claim construction, and evidence concerning the accused product’s labeling or induced use.

“Stable dose” is another potentially material limitation. A short-term or titrating levodopa regimen may create a claim-construction dispute. A generic label that instructs patients to continue existing levodopa therapy may create stronger induced-infringement exposure than a label that expressly excludes stable levodopa use.

What does each dependent claim add?

How does the 200 mg/day limitation affect patent scope?

Claim 4 adds a ceiling of approximately 200 mg/day. This limitation is commercially significant because it corresponds to a practical maximum for safinamide dosing and can capture a fixed-dose product even where a patient’s body weight makes the weight-based limitation less precise.

The relationship between the weight-based and fixed-dose limitations creates separate infringement pathways. A regimen may fall within the 0.5 to 5 mg/kg/day range but exceed 200 mg/day, or it may satisfy the 200 mg/day ceiling without satisfying the weight-based range in a particular patient. Claims 1 and 2 remain the principal claims because claim 4 depends on them.

Does claim 7 cover Xadago?

Yes. Claim 7 expressly covers safinamide methanesulfonate. Xadago contains safinamide as the methanesulfonate salt.[1] This substantially reduces the ability of a generic applicant to avoid the claim merely by using the commercial salt form.

A different pharmaceutically acceptable salt could still fall within claims 1 and 2 if it satisfies the other limitations. Claim 7 is narrower because it is limited to the methanesulfonate salt.

Do claims 8 through 10 cover common Parkinson’s regimens?

Yes. Claim 8 covers levodopa administered with carbidopa or benserazide. Claim 9 adds a COMT inhibitor, and claim 10 identifies tolcapone and entacapone.

These claims are narrower than claims 1 and 2. They may be relevant where a patient uses levodopa/carbidopa plus entacapone, a common form of adjunctive Parkinson’s therapy. They are less important to a basic Xadago product claim if the broader independent claims can be established without proof of a COMT inhibitor.

When does U.S. Patent 8,283,380 lose exclusivity?

The patent’s expected nominal expiration is approximately March 2027 based on the patent term associated with its priority and filing history. The controlling date is the official USPTO patent-term calculation, including any patent-term adjustment, terminal disclaimer, or other term-specific event.[2,3]

The patent term should be distinguished from FDA regulatory exclusivity:

Exclusivity right Relevant date or status
U.S. Patent 8,283,380 Expected to remain relevant until approximately March 2027, subject to the official term calculation
FDA new chemical entity exclusivity Ran from Xadago’s March 21, 2017 approval and generally expired after five years
Orphan-drug exclusivity Xadago was not approved under an orphan-drug exclusivity framework for the broad Parkinson’s indication
Pediatric exclusivity No six-month extension is established by the claim information supplied
Orange Book use patent Must be verified against the current FDA Orange Book entry

FDA approval does not itself establish patent validity. Conversely, expiration of NCE exclusivity does not eliminate a listed method-of-use patent.

What is the FDA and Orange Book status of Xadago?

The FDA approved Xadago on March 21, 2017, as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.[1] The approved product is safinamide tablets in 50 mg and 100 mg strengths.

The FDA-approved use closely tracks the commercial relevance of Patent 8,283,380:

  • Idiopathic Parkinson’s disease;
  • Continued levodopa therapy;
  • Adjunctive safinamide treatment;
  • Oral administration;
  • Once-daily use;
  • Dose escalation from 50 mg to 100 mg in appropriate patients.

Orange Book-listed method-of-use patents can expose an ANDA applicant to patent litigation even when the underlying compound patent has expired. A generic company may attempt a section viii statement carving out the patented indication, but that approach is difficult where the approved label and the patented use substantially overlap.[4]

The exact current Orange Book listing and any associated patent-use code should be confirmed from the FDA’s current electronic Orange Book. Patent listing status can change through delisting, expiration updates, corrections, or changes in the approved labeling.

Which companies are challenging the safinamide patent?

The claim set alone does not establish a current Paragraph IV challenger, active district-court litigation, or settlement agreement. Those facts require review of the current FDA ANDA records, Orange Book certifications, and federal court dockets.

For business purposes, the relevant challenger categories are:

  1. An ANDA applicant seeking approval for safinamide tablets;
  2. A section viii applicant carving out the patented adjunctive-use indication;
  3. A 505(b)(2) applicant proposing a modified safinamide indication or dosing regimen;
  4. A manufacturer contesting validity or enforceability under a Paragraph IV certification.

A Paragraph IV notice would normally trigger a patent-infringement action under the Hatch-Waxman framework. A timely suit could impose a statutory 30-month stay of FDA approval, subject to statutory exceptions and court developments.[5]

What generic launch risks exist?

At-risk launch

A generic company could launch before patent expiration after receiving a favorable invalidity or noninfringement ruling, or it could launch “at risk” while litigation remains unresolved. The commercial risk would include damages, an injunction, and exposure for induced infringement if the proposed label directs use with levodopa.

Label carve-out

A section viii carve-out may be viable only if the generic labeling omits the patented method. This strategy becomes weaker where the only commercially meaningful use is adjunctive treatment with levodopa and the FDA-approved label necessarily communicates concurrent use.

Noninfringing dosing

A label that uses a dose outside the claimed range may reduce literal infringement risk. That strategy can be undermined if the approved label permits titration into the patented range or if the patentee asserts infringement under the doctrine of equivalents.

Invalidity defenses

Potential validity issues include:

  • Obviousness based on prior clinical or pharmacological evidence concerning safinamide and levodopa;
  • Lack of written description or enablement for the claimed dosage range;
  • Indefiniteness concerning “about,” “stable dose,” or “concurrently”;
  • Anticipation by earlier safinamide Parkinson’s treatment disclosures;
  • Double-patenting or prosecution-history issues involving related family members.

The practical strength of these defenses depends on the prosecution record, prior-art dates, clinical data, and claim construction. The claim language alone is insufficient to predict litigation outcome.

How strong is the patent estate for safinamide?

Patent 8,283,380 has meaningful but narrow protection. Its strength comes from alignment with the commercial treatment regimen:

  • It covers adjunctive treatment rather than an obscure or noncommercial use.
  • Claim 7 reaches safinamide methanesulfonate.
  • Claim 6 reaches once-daily administration.
  • Claim 8 reaches levodopa/carbidopa and levodopa/benserazide regimens.
  • The dose limitations correspond broadly to clinical use.

Its weaknesses are equally clear:

  • It does not claim the safinamide molecule itself.
  • It is vulnerable to design-around arguments involving dose, indication, route, or labeling.
  • It requires proof of idiopathic Parkinson’s disease and concurrent stable levodopa therapy.
  • It may face obviousness challenges based on the known use of safinamide as an adjunct to levodopa.
  • The patent term is relatively close to the anticipated generic-entry window.

The estate should be analyzed together with any related safinamide compound, formulation, dosing, crystalline-form, manufacturing, and method-of-use patents. Patent 8,283,380 alone does not establish broad exclusivity over all safinamide products.

Does safinamide have biosimilar risk?

No. Safinamide is a chemically synthesized small molecule, not a biologic. The relevant competition pathway is an ANDA for a generic equivalent, not a biosimilar application under the Public Health Service Act.

The primary regulatory issues are bioequivalence, pharmaceutical equivalence, labeling, patent certification, and any relevant formulation differences. Manufacturing patents could still delay or complicate supply, but they would not convert safinamide into a biologic product.

What manufacturing and geographic barriers exist?

Patent 8,283,380 is primarily a U.S. method-of-use barrier. It does not, based on the supplied claims, claim:

  • Safinamide synthesis;
  • Safinamide methanesulfonate crystallization;
  • Tablet composition;
  • Packaging;
  • Manufacturing intermediates;
  • Non-U.S. treatment methods.

Geographic protection must be assessed separately by jurisdiction. A U.S. method patent does not prevent manufacture, sale, or use outside the United States unless separate foreign patents apply. Foreign family members may have different claim scope, expiration dates, opposition histories, and enforceability.

Manufacturing freedom to operate therefore requires a separate review of compound, salt, process, polymorph, formulation, and use patents in each target country.

What revenue exposure does the patent create?

The patent creates direct exposure for any U.S. generic launch that relies on the approved adjunctive Parkinson’s indication before the relevant patent term ends. The amount of revenue at risk depends on Xadago prescription volume, net price, payer coverage, generic substitution, and the number and timing of ANDA entrants.

A reliable revenue estimate cannot be derived from the patent claims. The patent establishes a legal barrier, not the size of the protected market. Commercial analysis should separate:

  • Brand revenue during the remaining patent term;
  • Revenue erosion after first generic entry;
  • Price compression after multiple generic entrants;
  • Potential authorized-generic competition;
  • Litigation settlement timing and launch restrictions.

Key Takeaways

  • U.S. Patent 8,283,380 is a method-of-treatment patent for oral safinamide used concurrently with stable levodopa in idiopathic Parkinson’s disease.
  • Claims 1 and 2 provide the core protection.
  • Dependent claims cover the 200 mg/day ceiling, at least 12 weeks of use, once-daily administration, safinamide methanesulfonate, carbidopa or benserazide, and COMT inhibitors.
  • Claim 7 directly covers the safinamide methanesulfonate form used in Xadago.
  • The patent does not claim safinamide as a chemical compound or cover safinamide monotherapy.
  • The expected nominal expiration is approximately March 2027, subject to the official USPTO term calculation.
  • The relevant generic pathway is an ANDA with Paragraph IV or section viii patent certification, not a biosimilar application.
  • Current challenger identities, litigation status, settlement terms, and Orange Book listings require current FDA and court-docket verification.
  • The patent is commercially relevant because its claims track the FDA-approved adjunctive use of Xadago, but its method-of-use structure leaves potential design-around and invalidity arguments.

FAQs

Can a generic safinamide product launch before March 2027?

Yes, but only if the applicant obtains approval without an enforceable patent barrier, wins or settles litigation, uses a valid indication carve-out, or launches at risk. Patent expiration alone does not determine the timing of FDA approval.

Does using safinamide without levodopa avoid Patent 8,283,380?

Generally, yes for the supplied claims. Claims 1 and 2 require concurrent levodopa treatment. Safinamide monotherapy would not satisfy that express limitation, although other patents or regulatory restrictions could remain relevant.

Does a 50 mg once-daily safinamide regimen fall within the claims?

It may. The answer depends on the patient’s weight and the applicable “about” range. A 50 mg daily dose generally falls within the claimed dosage concept for many patients, but infringement requires satisfaction of every limitation in the asserted claim.

Are claims 8 through 10 necessary to prove infringement of the main Xadago use?

No. Claims 8 through 10 add narrower limitations. Claims 1 and 2 do not require carbidopa, benserazide, or a COMT inhibitor, although those agents may support infringement of the dependent claims.

Does patent expiration eliminate all U.S. exclusivity for safinamide?

No. Expiration of Patent 8,283,380 would remove that patent barrier, but other unexpired patents, regulatory exclusivity, FDA approval requirements, manufacturing patents, or litigation outcomes could affect market entry.

References

  1. U.S. Food and Drug Administration. (2017). Xadago (safinamide) prescribing information. FDA.
  2. U.S. Patent No. 8,283,380. (2012). Methods for treating Parkinson’s disease. U.S. Patent and Trademark Office.
  3. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term expiration information. USPTO.
  4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
  5. 21 U.S.C. § 355(j). (2024). Abbreviated applications and patent certifications under the Federal Food, Drug, and Cosmetic Act.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 8,283,380

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mdd Us XADAGO safinamide mesylate TABLET;ORAL 207145-001 Mar 21, 2017 AB RX Yes No 8,283,380 ⤷  Start Trial ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES ⤷  Start Trial
Mdd Us XADAGO safinamide mesylate TABLET;ORAL 207145-002 Mar 21, 2017 AB RX Yes Yes 8,283,380 ⤷  Start Trial ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,283,380

PCT Information
PCT FiledApril 08, 2004PCT Application Number:PCT/IB2004/001408
PCT Publication Date:October 21, 2004PCT Publication Number: WO2004/089353

International Family Members for US Patent 8,283,380

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1613296 ⤷  Start Trial CA 2015 00042 Denmark ⤷  Start Trial
European Patent Office 1613296 ⤷  Start Trial 92782 Luxembourg ⤷  Start Trial
European Patent Office 1613296 ⤷  Start Trial 300752 Netherlands ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.